Lonza acquires Simbiosys Biowares' preclinical cell and molecular biology group

Saturday, 21 November, 2009 | Supplied by: Capsugel Australia Pty Ltd


Lonza has completed the acquisition of the preclinical cell and molecular biology assets of Simbiosys Biowares India, a biology outsourcing company, expanding its cell-biology platform.

Simbiosys’s cell and molecular biology group specialises in primary cell isolation and tissue sourcing and in performing preclinical services to mid-size pharmaceutical companies.

Simbiosys Biowares India offers preclinical services in the areas of: drug discovery services (includes lead validation and lead development using in-vitro and in-vivo ADME-Tox assays); molecular biology contract research services (including DNA amplification and cloning, DNA/RNA isolation, synthetic gene construction and quantitative PCR); biopharmaceutical services (includes process design optimisation of fermentation technology for producing small-molecules, proteins and mAbs for therapeutic, diagnostic and research applications).

Online: www.capsugel.com
Phone: 1300 657508
Related Products

Enzo Life Sciences SUPERKILLERTRAIL protein (soluble) (human), (recombinant)

Enzo Life Sciences' SUPERKILLERTRAIL (soluble) (human), (recombinant) is an enhanced ligand...

Diaclone ELISpot Kits

Diaclone's ELISpot Kits are highly specific immunoassays for the analysis of the production...

Bio-Rad Laboratories Bio-Plex Pro Human SARS-CoV-2 Variant Neutralization Antibody Assays

The assays allow scientists to measure neutralising antibodies quickly and efficiently against...


  • All content Copyright © 2022 Westwick-Farrow Pty Ltd